NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care

Inclusion criteria

• Age ≥18 years at the time of signing the informed consent
• Diagnosis of SLE
• Prescription of anifrolumab SC in line with the european summary of product characteristics (SmPC)
• Prescription of anifrolumab SC was decided prior to and independently of the study
• Signed and dated written informed consent prior to enrolment into the study
• Willing and able to participate in all study evaluations and procedures

Exclusion criteria

• Prior exposure to anifrolumab
• Treatment with concurrent biologics
• Current or planned participation in a clinical study that does not constitute routine care
• Currently experiencing a severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy (mycophenolate mofetil \[MMF\]/cyclophosphamide + high dose steroids), isolated Class V lupus nephritis (in absence of other SLE manifestations, i.e. skin/joint involvement), or active severe or unstable neuropsychiatric lupus
• Conditions (acute or chronic) or events at the time of signing the informed consent that would limit the patient's ability to complete questionnaires or participate in this study over the period of 24 months according to the treating physician (e.g., clinically significant cognitive impairment or dementia, unstable severe psychiatric illness, uncontrolled alcohol or substance use disorder that interferes with adherence to care or other circumstances that preclude completing PROs or attending routine visits)
• Pregnancy or breast feeding at study enrolment